NASDAQ:ONCS - OncoSec Medical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.6250 -0.01 (-1.57 %)
(As of 02/19/2019 04:00 PM ET)
Previous Close$0.63
Today's Range$0.60 - $0.6499
52-Week Range$0.54 - $2.21
Volume265,630 shs
Average Volume666,850 shs
Market Capitalization$40.32 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.

Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCS
CUSIPN/A
Phone855-662-6732

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.44 per share

Profitability

Net Income$-39,130,000.00

Miscellaneous

Employees34
Market Cap$40.32 million
OptionableNot Optionable

OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Inc (NASDAQ:ONCS) released its quarterly earnings data on Friday, December, 14th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.06. View OncoSec Medical's Earnings History.

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release their next quarterly earnings announcement on Friday, March 8th 2019. View Earnings Estimates for OncoSec Medical.

What price target have analysts set for ONCS?

4 equities research analysts have issued 1 year price objectives for OncoSec Medical's shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate OncoSec Medical's share price to reach $4.00 in the next year. This suggests a possible upside of 540.0% from the stock's current price. View Analyst Price Targets for OncoSec Medical.

What is the consensus analysts' recommendation for OncoSec Medical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoSec Medical.

Has OncoSec Medical been receiving favorable news coverage?

Media headlines about ONCS stock have been trending somewhat positive on Tuesday, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. OncoSec Medical earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are some of OncoSec Medical's key competitors?

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the folowing people:
  • Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
  • Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 54)
  • Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 38)
  • Ms. Sara M. Bonstein, CFO & COO (Age 37)
  • Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.75%), Geode Capital Management LLC (0.60%), Northern Trust Corp (0.18%), Bank of New York Mellon Corp (0.16%), Moloney Securities Asset Management LLC (0.08%) and Millennium Management LLC (0.06%). Company insiders that own OncoSec Medical stock include Avtar S Dhillon, Daniel J O'connor, James M Demesa, Punit Dhillon and Richard B Slansky. View Institutional Ownership Trends for OncoSec Medical.

Which institutional investors are selling OncoSec Medical stock?

ONCS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have sold OncoSec Medical company stock in the last year include Avtar S Dhillon, Punit Dhillon and Richard B Slansky. View Insider Buying and Selling for OncoSec Medical.

Which institutional investors are buying OncoSec Medical stock?

ONCS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Bank of New York Mellon Corp, Northern Trust Corp and Moloney Securities Asset Management LLC. Company insiders that have bought OncoSec Medical stock in the last two years include Daniel J O'connor, James M Demesa and Punit Dhillon. View Insider Buying and Selling for OncoSec Medical.

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $0.6250.

How big of a company is OncoSec Medical?

OncoSec Medical has a market capitalization of $40.32 million. OncoSec Medical employs 34 workers across the globe.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is http://www.oncosec.com.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]


MarketBeat Community Rating for OncoSec Medical (NASDAQ ONCS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  423
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe ONCS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel